Volume | 398,714 |
|
|||||
News | - | ||||||
Day High | 6.15 | Low High |
|||||
Day Low | 5.86 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Black Diamond Therapeutics Inc | BDTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
6.06 | 5.86 | 6.15 | 5.97 | 6.17 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
4,716 | 398,714 | US$ 5.99 | US$ 2,388,659 | - | 1.62 - 7.66 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:16:53 | 25 | US$ 6.16 | USD |
Black Diamond Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
308.76M | 51.72M | - | 0 | -82.44M | -1.59 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Black Diamond Therapeutics News
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BDTX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.65 | 6.41 | 4.61 | 5.89 | 993,861 | 1.35 | 29.03% |
1 Month | 5.25 | 6.41 | 4.41 | 5.24 | 682,899 | 0.75 | 14.29% |
3 Months | 5.33 | 7.66 | 4.41 | 5.57 | 690,206 | 0.67 | 12.57% |
6 Months | 2.64 | 7.66 | 2.53 | 4.82 | 629,613 | 3.36 | 127.27% |
1 Year | 2.11 | 7.66 | 1.62 | 5.26 | 1,536,628 | 3.89 | 184.36% |
3 Years | 12.90 | 13.29 | 1.18 | 5.31 | 685,159 | -6.90 | -53.49% |
5 Years | 33.00 | 46.25 | 1.18 | 9.23 | 576,470 | -27.00 | -81.82% |
Black Diamond Therapeutics Description
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under pipeline are BDTX-189 and BDTX-1535. |